Abstract
Diabetes Mellitus (DM) is more common among individuals with severe mental illness (SMI). We aimed to assess quality-of-care-indicators in individuals with SMI following the 2015 Israel’s Mental-Health-reform. We analyzed yearly changes in 2015–2019 of quality-of-care-measures and intermediate-DM-outcomes, with adjustment for gender, age-group, and socioeconomic status (SES) and compared individuals with SMI to the general adult population. Adults with SMI had higher prevalences of DM (odds ratio (OR) = 1.64; 95% confidence intervals (CI): 1.61–1.67) and obesity (OR = 2.11; 95% CI: 2.08–2.13), compared to the general population. DM prevalence, DM control, and obesity rates increased over the years in this population. In 2019, HbA1c testing was marginally lower (OR = 0.88; 95% CI: 0.83–0.94) and uncontrolled DM (HbA1c > 9%) slightly more common among patients with SMI (OR = 1.22; 95% CI: 1.14–1.30), control worsened by decreasing SES. After adjustment, uncontrolled DM (adj. OR = 1.02; 95% CI: 0.96–1.09) was not associated with SMI. Cardio-metabolic morbidity among patients with SMI may be related to high prevalences of obesity and DM rather than poor DM control. Effective screening for metabolic diseases in this population and social reforms are required.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Afzal, M., Siddiqi, N., Ahmad, B., Afsheen, N., Aslam, F., Ali, A., et al. (2021). Prevalence of overweight and obesity in people with severe mental illness: Systematic review and meta-analysis. Frontiers in Endocrinology. https://doi.org/10.3389/fendo.2021.769309
Aviram, U., & Azary-Viesel, S. (2018). Mental health reform in Israel: Challenge and opportunity part ii: implementation of the reform—issues and problems. Israel Journal of Psychiatry, 55(3), 55–64.
Barnett, A. H., Mackin, P., Chaudhry, I., Farooqi, A., Gadsby, R., Heald, A., et al. (2007). Minimising metabolic and cardiovascular risk in schizophrenia: Diabetes, obesity and dyslipidaemia. Journal of Psychopharmacology, 21(4), 357–373. https://doi.org/10.1177/0269881107075509
Blanchard, E., & Samaras, K. (2014). Double jeopardy: Diabetes and severe mental illness. addressing the special needs of this vulnerable group. Diabetes Management, 4(4), 339–353. https://doi.org/10.2217/dmt.14.24
Brink, M., Green, A., Bojesen, A. B., Lamberti, J. S., Conwell, Y., & Andersen, K. (2019). Excess medical comorbidity and mortality across the lifespan in schizophrenia.: A nationwide danish register study. Schizophrenia Research, 206, 347–354. https://doi.org/10.1016/j.schres.2018.10.020.
Brown, C., Geiszler, L. C., Lewis, K. J., & Arbesman, M. (2018). Effectiveness of interventions for weight loss for people with serious mental illness: A systematic review and meta-analysis. American Journal of Occupational Therapy. https://doi.org/10.5014/ajot.2018.033415
Bushe, C., & Holt, R. (2004). Prevalence of diabetes and impaired glucose tolerance in patients with schizophrenia. British Journal of Psychiatry, 184(SUPPL. 47), S67–S71. https://doi.org/10.1192/bjp.184.47.s67.
Butterworth, P. (2003). The prevalence of mental disorders among income support recipients: An important issue for welfare reform. Australian and New Zealand Journal of Public Health, 27(4), 441–448. https://doi.org/10.1111/j.1467-842X.2003.tb00424.x.
Castillo-Sánchez, M., Fàbregas-Escurriola, M., Bergè-Baquero, D., Fernández-SanMartín, M., & Goday-Arno, A. (2017). Screening of cardiovascular risk factors in patients with schizophrenia and patients treated with antipsychotic drugs: Are we equally exhaustive as with the general population? Clinical and Experimental Hypertension, 39(5), 441–447. https://doi.org/10.1080/10641963.2016.1267200.
Central Bureau of Statistics. Socio-economic index. (2022). https://www.cbs.gov.il/en/subjects/Pages/Socio-Economic-Index-of-Local-Authorities.aspx. Accessed 22 September 2022.
Chesney, E., Goodwin, G. M., & Fazel, S. (2014). Risks of all-cause and suicide mortality in mental disorders: A meta-review. World Psychiatry, 13(2), 153–160. https://doi.org/10.1002/wps.20128.
Clarfield, A. M., Manor, O., Nun, G., Bin, Shvarts, S., Azzam, Z. S., Afek, A., et al. (2017). Health and health care in Israel: An introduction. The Lancet, 389(10088), 2503–2513. https://doi.org/10.1016/S0140-6736(17)30636-0.
Cohen, A., Ashworth, M., Askey, A., & Ismail, K. (2018). Diabetes outcomes in people with severe mental illness. British Journal of General Practice, 68(669), 166–167. https://doi.org/10.3399/bjgp18X695381.
De Hert, M., Dekker, J. M., Wood, D., Kahl, K. G., Holt, R. I. G., & Möller, H. J. (2009). Cardiovascular disease and diabetes in people with severe mental illness position statement from the european Psychiatric Association (EPA), supported by the European Association for the study of diabetes (EASD) and the European Society of Cardiology (ESC. European Psychiatry, 24(6), 412–424. https://doi.org/10.1016/j.eurpsy.2009.01.005.
Desai, M. M., Rosenheck, R. A., Druss, B. G., & Perlin, J. B. (2002). Mental disorders and quality of diabetes care in the veterans health administration. American Journal of Psychiatry, 159(9), 1584–1590. https://doi.org/10.1176/appi.ajp.159.9.1584.
Dickerson, F., Origoni, A., Schroeder, J., Schweinfurth, L. A. B., Stallings, C., Savage, C. L. G., et al. (2016). Mortality in schizophrenia and bipolar disorder: Clinical and serological predictors. Schizophrenia Research, 170(1), 177–183. https://doi.org/10.1016/j.schres.2015.11.010.
Dinan, T., Holt, R., Kohen, D., Thakore, J., Haddad, P., Baker, R., et al. (2004). Schizophrenia and diabetes 2003” expert consensus meeting, Dublin, 3–4 october 2003: Consensus summary. British Journal of Psychiatry. https://doi.org/10.1192/bjp.184.47.s112
Dixon, L. B., Kreyenbuhl, J. A., Dickerson, F. B., Donner, T. W., Brown, C. H., Wolheiter, K., et al. (2004). A comparison of type 2 diabetes outcomes among persons with and without severe mental illnesses. Psychiatric Services, 55(8), 892–900. https://doi.org/10.1176/appi.ps.55.8.892.
Eckel, R. H., Alberti, K. G. M. M., Grundy, S. M., & Zimmet, P. Z. (2010). The metabolic syndrome. The Lancet. https://doi.org/10.1016/S0140-6736(09)61794-3.
Fernández Guijarro, S., Miguel García, C., Pomarol-Clotet, E., Egea López, E. N., Martí, B., M. D., & Rigol Cuadra, M. A. (2020). Metabolic syndrome screening in people with severe Mental illness: Results from two Spanish Community Mental Health Centers. Journal of the American Psychiatric Nurses Association, 26(2), 162–171. https://doi.org/10.1177/1078390319826686.
Frayne, S. M., Halanych, J. H., Miller, D. R., Wang, F., Lin, H., Pogach, L., et al. (2005). Disparities in diabetes care: Impact of mental illness. Archives of Internal Medicine, 165(22), 2631–2638. https://doi.org/10.1001/archinte.165.22.2631.
Gal, G., Levav, I., & Kodesh, A. (2022). Impact of the mental health reform in Israel on health care and mortality among people with severe mental illness. Research Square preprint. https://doi.org/10.21203/rs.3.rs-2230826/v1.
Goldberg, R. W., Kreyenbuhl, J. A., Medoff, D. R., Dickerson, F. B., Wohlheiter, K., Fang, L. J., et al. (2007). Quality of diabetes care among adults with serious mental illness. Psychiatric Services, 58(4), 536–543. https://doi.org/10.1176/ps.2007.58.4.536.
Han, L., Doran, T., Holt, R. I. G., Hewitt, C., Jacobs, R., Prady, S. L., et al. (2021). Impact of severe mental illness on healthcare use and health outcomes for people with type 2 diabetes: A longitudinal observational study in England. British Journal of General Practice, 71(709), E565–E573. https://doi.org/10.3399/BJGP.2020.0884.
Holt, R. I. G., & Peveler, R. C. (2006). Association between antipsychotic drugs and diabetes. Diabetes Obesity and Metabolism, 8(2), 125–135. https://doi.org/10.1111/j.1463-1326.2005.00495.x.
Holt, R. I. G., & Peveler, R. C. (2011). Metabolic syndrome and Mental Illness. The Metabolic Syndrome: Second Edition, 177–193. https://doi.org/10.1002/9781444347319.ch11.
Israel Health Indicators (2022). Israel National Program for Quality Indicators in Community Healthcare website. https://en.israelhealthindicators.org/. Accessed 22 September 2022.
Jafari, S., Fernandez-Enright, F., & Huang, X. F. (2012). Structural contributions of antipsychotic drugs to their therapeutic profiles and metabolic side effects. Journal of Neurochemistry, 120(3), 371–384. https://doi.org/10.1111/j.1471-4159.2011.07590.x.
Jaffe, D. H., Shmueli, A., Ben-Yehuda, A., Paltiel, O., Calderon, R., Cohen, A. D., et al. (2012). Community healthcare in Israel: Quality indicators 2007–2009. Israel Journal of Health Policy Research, 1(1), 3. https://doi.org/10.1186/2045-4015-1-3.
Jones, S., Howard, L., & Thornicroft, G. (2008). Diagnostic overshadowing”: Worse physical health care for people with mental illness. Acta Psychiatrica Scandinavica. https://doi.org/10.1111/j.1600-0447.2008.01211.x.
Jørgensen, M., Mainz, J., Carinci, F., Thomsen, R. W., & Johnsen, S. P. (2018). Quality and predictors of diabetes care among patients with schizophrenia: A danish nationwide study. Psychiatric Services, 69(2), 179–185. https://doi.org/10.1176/appi.ps.201600460.
Kodesh, A., Goldshtein, I., Gelkopf, M., Goren, I., Chodick, G., & Shalev, V. (2012). Epidemiology and comorbidity of severe mental illnesses in the community: Findings from a computerized mental health registry in a large israeli health organization. Social Psychiatry and Psychiatric Epidemiology, 47(11), 1775–1782. https://doi.org/10.1007/s00127-012-0478-9.
Kovess, V., Gysens, S., Poinsard, R., Chanoit, P. F., & Labarte, S. (1999). Mental health and use of care in people receiving a french social benefit. Social Psychiatry and Psychiatric Epidemiology, 34(11), 588–594. https://doi.org/10.1007/s001270050179.
Krein, S. L., Bingham, C. R., McCarthy, J. F., Mitchinson, A., Payes, J., & Valenstein, M. (2006). Diabetes treatment among VA patients with comorbid serious mental illness. Psychiatric Services, 57(7), 1016–1021. https://doi.org/10.1176/ps.2006.57.7.1016.
Lindenmayer, J. P., Nathan, A. M., & Smith, R. C. (2001). Hyperglycemia associated with the use of atypical antipsychotics. Journal of Clinical Psychiatry, 62(SUPPL), 30–38.
Lund, C., Breen, A., Flisher, A. J., Kakuma, R., Corrigall, J., Joska, J. A., et al. (2010). Poverty and common mental disorders in low and middle income countries: A systematic review. Social Science and Medicine, 71(3), 517–528. https://doi.org/10.1016/j.socscimed.2010.04.027.
Lurie, I., Shoval, G., Hoshen, M., Balicer, R., Weiser, M., Weizman, A., & Krivoy, A. (2021). The association of medical resource utilization with physical morbidity and premature mortality among patients with schizophrenia: An historical prospective population cohort study. Schizophrenia Research. https://doi.org/10.1016/j.schres.2021.08.019.
Mangurian, C., Schillinger, D., Newcomer, J. W., Vittinghoff, E., Essock, S., Zhu, Z., et al. (2020). Comorbid diabetes and severe Mental illness: Outcomes in an Integrated Health Care Delivery System. Journal of General Internal Medicine, 35(1), 160–166. https://doi.org/10.1007/s11606-019-05489-3.
Martin, J. L., McLean, G., Park, J., Martin, D. J., Connolly, M., Mercer, S. W., & Smith, D. J. (2014). Impact of socioeconomic deprivation on rate and cause of death in severe mental illness. Bmc Psychiatry. https://doi.org/10.1186/s12888-014-0261-4
McGinty, E. E., Baller, J., Azrin, S. T., Juliano-Bult, D., & Daumit, G. L. (2015). Quality of medical care for persons with serious mental illness: A comprehensive review. Schizophrenia Research, 165(2–3), 227–235. https://doi.org/10.1016/j.schres.2015.04.010.
McIntyre, R. S., Konarski, J. Z., Misener, V. L., & Kennedy, S. H. (2005). Bipolar disorder and diabetes mellitus: Epidemiology, etiology, and treatment implications. Annals of Clinical Psychiatry, 17(2), 83–93. https://doi.org/10.1080/10401230590932380.
Melkersson, K., & Dahl, M. L. (2004). Adverse metabolic effects associated with atypical antipsychotics: Literature review and clinical implications. Drugs, 64(7), 701–723. https://doi.org/10.2165/00003495-200464070-00003.
Ministry of health (2019). Mental Health in Israel- Statistical abstract. https://www.health.gov.il/PublicationsFiles/mtl-yearbook-2019.pdf. Accessed 22 September 2022.
Ministry of Health (2015). Mental Health Reform- Israeli Ministry of Health. https://www.health.gov.il/English/Topics/Mental_Health/Pages/default.aspx. Accessed 22 September 2022.
Mir, S., & Taylor, D. (2001). Atypical antipsychotics and hyperglycaemia. International Clinical Psychopharmacology, 16(2), 63–74. https://doi.org/10.1097/00004850-200103000-00001.
Mitchell, A. J., Malone, D., & Doebbeling, C. C. (2009). Quality of medical care for people with and without comorbid mental illness and substance misuse: Systematic review of comparative studies. British Journal of Psychiatry, 194(6), 491–499. https://doi.org/10.1192/bjp.bp.107.045732.
Mulligan, K., McBain, H., Lamontagne-Godwin, F., Chapman, J., Haddad, M., Jones, J., et al. (2017). Barriers and enablers of type 2 diabetes self-management in people with severe mental illness. Health Expectations, 20(5), 1020–1030. https://doi.org/10.1111/hex.12543.
Nasrallah, H. A., Meyer, J. M., Goff, D. C., McEvoy, J. P., Davis, S. M., Stroup, T. S., & Lieberman, J. A. (2006). Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: Data from the CATIE schizophrenia trial sample at baseline. Schizophrenia Research, 86(1–3), 15–22. https://doi.org/10.1016/j.schres.2006.06.026.
National Diabetes Audit (2020). National Diabetes Audit- Care Processes and Treatment Targets 2019–2020, Interactive report. https://digital.nhs.uk/data-and-information/publications/statistical/national-diabetes-audit/care-processes-and-treatment-targets-3rd-quarter-january-december-2020-data-release. Accessed 22 September 2022.
National Quality Use of Medicines, & Indicators, A. H. (2014). Percentage of patients taking antipsychotic medicines who receive appropriate monitoring for the development of metabolic side effects- Australian Commission on Safety and Quality in Health Care. https://www.safetyandquality.gov.au/sites/default/files/migrated/SAQ127_Indicators_7.4.docx. Accessed 22 September 2022.
Ng-Mak, D., & Rajagopalan, K. (2019). Examining quality of care for individuals treated for mental health using the HEDIS mental health quality measures. Current Medical Research and Opinion, 35(1), 87–95. https://doi.org/10.1080/03007995.2018.1532883.
NHS (2021). Quality and Outcomes Framework (QOF) - NHS Digital. The NHS Outcomes Framework. https://digital.nhs.uk/data-and-information/data-tools-and-services/data-services/general-practice-data-hub/quality-outcomes-framework-qof. Accessed 22 September 2022.
NICE (2014). National Institute for Health and Care Excellence. Psychosis and schizophrenia in adults: prevention and management. https://www.nice.org.uk/guidance/cg178. Accessed 22 September 2022.
NICE (2022). NICE recommended care processes. http://www.nice.org.uk/guidance/conditions-and-diseases/diabetes-and-other-endocrinal--nutritional-and-metabolic-conditions/diabetes. Accessed 22 September 2022.
O’Neill, S., & O’Driscoll, L. (2015). Metabolic syndrome: A closer look at the growing epidemic and its associated pathologies. Obesity Reviews, 16(1), 1–12. https://doi.org/10.1111/obr.12229.
Points Location Intelligence (September 2022). (n.d.). https://points.co.il/. Accessed 22.
Rathmann, W., Pscherer, S., Konrad, M., & Kostev, K. (2016). Diabetes treatment in people with type 2 diabetes and schizophrenia: Retrospective primary care database analyses. Primary Care Diabetes, 10(1), 36–40. https://doi.org/10.1016/j.pcd.2015.04.001.
Regenold, W. T., Thapar, R. K., Marano, C., Gavirneni, S., & Kondapavuluru, P. V. (2002). Increased prevalence of type 2 diabetes mellitus among psychiatric inpatients with bipolar I affective and schizoaffective disorders independent of psychotropic drug use. Journal of Affective Disorders, 70(1), 19–26. https://doi.org/10.1016/S0165-0327(01)00456-6.
Reiss, F. (2013). Socioeconomic inequalities and mental health problems in children and adolescents: A systematic review. Social Science and Medicine. https://doi.org/10.1016/j.socscimed.2013.04.026.
Russell, J. M., & Mackell, J. A. (2001). Bodyweight gain associated with atypical antipsychotics: Epidemiology and therapeutic implications. Cns Drugs, 15(7), 537–551. https://doi.org/10.2165/00023210-200115070-00004.
Schmidt, E. M., Barnes, J., Chen, C., Trafton, J., Frayne, S., & Harris, A. H. S. (2019). Patient and Health Care factors Associated with Long-term Diabetes Complications among adults with and without Mental Health and Substance Use Disorders. JAMA Network Open, 2(9), e1912060. https://doi.org/10.1001/jamanetworkopen.2019.12060.
Scott, D., & Happell, B. (2011). The high prevalence of poor physical health and unhealthy lifestyle behaviours in individuals with severe mental illness. Issues in Mental Health Nursing, 32(9), 589–597. https://doi.org/10.3109/01612840.2011.569846.
Smith, R., Han, L., Ali, S., Prady, S. L., Taylor, J., Hughes, T., et al. (2019). Glucose, cholesterol and blood pressure in type II diabetes: A longitudinal observational study comparing patients with and without severe mental illness. Journal of Psychiatric and Mental Health Nursing, 26, 347–357. https://doi.org/10.1111/jpm.12546.
Toalson, P., Ahmed, S., Hardy, T., & Kabinoff, G. (2004). The metabolic syndrome in patients with severe Mental Illnesses. The Primary Care Companion For CNS Disorders. https://doi.org/10.4088/pcc.v06n0402
VA, H. (2020). Health Disparities in Quality Indicators of Healthcare Among Adults with Mental Illness. https://www.hsrd.research.va.gov/publications/esp/health_disparitiesMH-REPORT.pdf. Accessed 22 September 2022.
Van Winkel, R., De Hert, M., Van Eyck, D., Hanssens, L., Wampers, M., Scheen, A., & Peuskens, J. (2006). Screening for diabetes and other metabolic abnormalities in patients with schizophrenia and schizoaffective disorder: Evaluation of incidence and screening methods. Journal of Clinical Psychiatry, 67(10), 1493–1500. https://doi.org/10.4088/JCP.v67n1002.
Van Winkel, R., De Hert, M., Van Eyck, D., Hanssens, L., Wampers, M., Scheen, A., & Peuskens, J. (2008). Prevalence of diabetes and the metabolic syndrome in a sample of patients with bipolar disorder. Bipolar Disorders, 10(2), 342–348. https://doi.org/10.1111/j.1399-5618.2007.00520.x.
Vancampfort, D., Correll, C. U., Galling, B., Probst, M., De Hert, M., Ward, P. B., et al. (2016). Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: A systematic review and large scale meta-analysis. World Psychiatry, 15(2), 166–174. https://doi.org/10.1002/wps.20309.
Vedal, T. S. J., Steen, N. E., Birkeland, K. I., Dieset, I., Reponen, E. J., Laskemoen, J. F., et al. (2019). Adipokine levels are associated with insulin resistance in antipsychotics users independently of BMI. Psychoneuroendocrinology, 103, 87–95. https://doi.org/10.1016/j.psyneuen.2019.01.001.
Verhaeghe, N., De Maeseneer, J., Maes, L., Van Heeringen, C., & Annemans, L. (2011). Effectiveness and cost-effectiveness of lifestyle interventions on physical activity and eating habits in persons with severe mental disorders: A systematic review. International Journal of Behavioral Nutrition and Physical Activity. https://doi.org/10.1186/1479-5868-8-28
Vinogradova, Y., Coupland, C., Hippisley-Cox, J., Whyte, S., & Penny, C. (2010). Effects of severe mental illness on survival of people with diabetes. British Journal of Psychiatry, 197(4), 272–277. https://doi.org/10.1192/bjp.bp.109.074674.
Wake, D. J., Broughton, P., Perera, S. M., MacIntyre, D. J., & Leese, G. P. (2016). Altered metabolic parameters in association with antipsychotic medication use in diabetes: A population based case-control study. Psychoneuroendocrinology, 66, 214–220. https://doi.org/10.1016/j.psyneuen.2016.01.022.
Ward, M., & Druss, B. (2015). The epidemiology of diabetes in psychotic disorders. The Lancet Psychiatry. https://doi.org/10.1016/S2215-0366(15)00007-3.
Wetterling, T. (2001). Bodyweight gain with atypical antipsychotics: A comparative review. Drug Safety. https://doi.org/10.2165/00002018-200124010-00005.
WHO (2018). Management of physical health conditions in adults with severe mental disorders WHO GUIDELINES. Who.
Acknowledgements
We would like to thank the National Institute for Healthcare Policy and Research and the Health Council for their supervision and support. The conclusions of this work were presented at the 14th Annual Health Policy Conference of the National Institute for Healthcare Policy and Research.
Funding
Grant from the National Institute for Healthcare Policy and Research.
Competing InterestsAll the authors declare that they have no financial or non-financial competing interests that relate to the research described in this paper. All results are derived from national-level data that were not influenced by any institution.
Ethical approvalThis study relied upon de-identified data that are used for ongoing quality measurement purposes, no ethical approval was required.
Author information
Authors and Affiliations
Contributions
All authors read and approved the final manuscript. DBB made substantial contributions to formal analysis and interpretation of the data and was a major contributor in writing the manuscript and visualization of the published work; EEM made substantial contributions to methodology and formal analysis of the data and revised the manuscript; RCM made substantial contributions to the conceptualization and supervision of the research, interpretation of the data, and revised the manuscript; AJR, MK, SBG, ABY, OM made substantial contributions to the interpretation of the data and revised the manuscript; ADC, EBR, RB, EM made substantial contributions to the data provision and revised the manuscript; OP made substantial contributions to the conceptualization, methodology and supervision of the research, to interpretation of the data, and was a major contributor in writing the manuscript.
Corresponding author
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Barasche-Berdah, D., Ein-Mor, E., Calderon-Margalit, R. et al. Nationwide Evaluation of Quality of Care Indicators for Individuals with Severe Mental Illness and Diabetes Mellitus, Following Israel’s Mental Health Reform. Community Ment Health J 60, 354–365 (2024). https://doi.org/10.1007/s10597-023-01178-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10597-023-01178-y